ClinicalTrials.gg
CompletedNCT06170242Updated Oct 7, 2025Results posted

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

A Phase 2 interventional study of EDP-323 Dose Regimen 1 and EDP-323 Dose Regimen 2 in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc — 1 open to participants now, 1 under way, none of them phase 3. Respiratory Syncytial Virus Infections · Enanta Pharmaceuticals, Inc.

Enrollment
4th of 14
142 · median 77
Started
2023
the only one that year
Phase 2
5 of 14
1 open now
Registered
10th of 14
by date

Among the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, this one is the 4th largest by enrollment, is the only one that started in 2023, is one of 5 in phase 2, and was the 10th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, or all of them as a file.
02

Study summary

A randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-323 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to assess the antiviral effect of EDP-323 compared to a placebo control in the respiratory syncytial virus challenge model.

03

Conditions studied

  • RSV Infection

Keywords

  • challenge study
  • RSV
  • antiviral
  • RSV-A Memphis 37b
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document signed and dated by the subject.
  • Age 18 to 55 years, inclusive.
  • In good health with no history of major medical conditions.
  • A total body weight ≥ 50 kg and (BMI) ≥ 18 kg/m2 and ≤ 35kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing females
  • Acute or chronic medical illness
  • History of, or currently active, symptoms or signs suggestive of upper or lower respiratory tract (URT or LRT) infection within 4 weeks prior to the first study visit.
  • Abnormal lung function
  • Positive for , active or C test
  • Nose or nasopharynx abnormalities
  • Receipt of any drug within 3 months prior to the planned date of viral challenge/first dose of study drug
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    EDP-323 Arm A

    Subjects will take EDP-323 Dose 1 orally for 5 days

    Drug: EDP-323 Dose Regimen 1

  • Experimental
    EDP-323 Arm B

    Subjects will take EDP-323 Dose 2 orally for 5 days

    Drug: EDP-323 Dose Regimen 2

  • Placebo comparator
    Placebo Arm C

    Subjects will take matching placebo orally for 5 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC)

    Measured by qRT-PCR in nasal samples.

    Time frame: Day 1 to Day 12

Secondary outcomes

  1. qRT-PCR: RSV Peak Viral Load (VLPEAK)

    Measured by qRT-PCR in nasal samples.

    Time frame: Day 1 to Day 12

  2. qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK

    Measured by qRT-PCR in nasal samples.

    Time frame: Day 1 to Day 12

  3. qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity

    The time from the assessment at the time of the first dose of IMP to qRT-viral load negativity was analyzed using the Kaplan-Meier method. Viral load negativity was reached at the first time when the viral load was undetectable (\< lower limit of detection \[LLOD\]) by qRT-PCR, after which no further detectable assessment appeared. Measured by qRT-PCR in nasal samples.

    Time frame: Day 1 to Day 12

  4. qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load

    Time to first negative slope = time of the timepoint after which there are two consecutive declines in viral load - time of the nearest viral load assessment to the first dose of IMP. Measured by qRT-PCR in nasal samples.

    Time frame: Day 1 to Day 12

  5. qRT-PCR: RSV Viral Load Clearance Rate - EDP-323 High Dose

    Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. The model was a distinct analysis for the EDP-323 high dose and placebo groups where the estimates for both groups are model-dependent and impacted by the overall model. A negative slope indicated that the viral load decreased over time. Measured by qRT-PCR in nasal samples.

    Time frame: Up to Day 16

  6. qRT-PCR: RSV Viral Load Clearance Rate - EDP-323 Low Dose

    Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. The model was a distinct analysis for the EDP-323 low dose and placebo groups where the estimates for both groups are model-dependent and impacted by the overall model. A negative slope indicated that the viral load decreased over time. Measured by qRT-PCR in nasal samples.

    Time frame: Up to Day 16

  7. Viral Culture: RSV VL-AUC

    Measured by viral culture (plaque assay) in nasal samples.

    Time frame: Day 1 to Day 12

  8. Viral Culture: RSV VLPEAK

    Measured by viral culture (plaque assay) in nasal samples.

    Time frame: Day 1 to Day 12

  9. Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK

    Measured by viral culture (plaque assay) in nasal samples.

    Time frame: Day 1 to Day 12

  10. Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity

    Measured by viral culture (plaque assay) in nasal samples.

    Time frame: Day 1 to Day 12

  11. Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load

    Measured by viral culture (plaque assay) in nasal samples.

    Time frame: Day 1 to Day 12

  12. Viral Culture: RSV Viral Load Clearance Rate

    Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. A negative slope indicated that the viral load decreased over time. Measured by viral culture in nasal samples.

    Time frame: Up to Day 16

  13. Area Under the Total Symptom Score (TSS)-Time Curve (TSS-AUC)

    An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome. The calculation of the TSS-AUC was performed on the TSS measured 3 times a day using the trapezoidal summation rule based on actual time intervals in hours.

    Time frame: Day 1 to Day 12

  14. Peak TSS

    Defined as the highest recorded value of TSS. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.

    Time frame: Day 1 to Day 12

  15. Time to Peak TSS

    Time to peak TSS = time of peak TSS - time of the nearest TSS assessment to the first dose of IMP. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.

    Time frame: Day 1 to Day 12

  16. Time to Resolution From Peak TSS

    Time to resolution from peak TSS = time of the first 24-hour symptom-free time point - time of peak TSS. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.

    Time frame: Day 1 to Day 12

  17. Total Weight of Nasal Discharge (Mucus) Produced

    Each participant was given pre-weighed packets of paper tissues. Participants were asked to place single tissues used for nose blowing or sneezing into a specified collection bag (for that participant only).

    Time frame: Day 1 to Day 12

  18. Total Number of Tissues Used

    Each participant was given pre-weighed packets of paper tissues. Participants were asked to place single tissues used for nose blowing or sneezing into a specified collection bag (for that participant only).

    Time frame: Day 1 to Day 12

  19. Maximum Plasma Concentration (Cmax)

    Plasma pharmacokinetic (PK) parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, below the limit of quantification (BQL) values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

    Time frame: First Dose: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose) and Day 2 pre-dose; Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)

  20. Time to Cmax (Tmax)

    Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

    Time frame: First Dose: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose) and Day 2 pre-dose; Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)

  21. Terminal Half-life (t1/2)

    Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)

  22. Apparent Systemic Clearance at Steady-state (CLss/F)

    Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)

  23. Terminal Elimination Rate Constant (λz)

    Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)

  24. Apparent Volume of Distribution at Steady-state (Vss/F)

    Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)

  25. Plasma Concentration at 12 Hours (C12h) and 24 Hours (C24h)

    In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

    Time frame: First Dose: Day 1, 12 and 24 hours post-dose; Last Dose: Day 5, 12 and 24 hours post-dose

  26. Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last)

    Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The AUCs were calculated using linear up/log down method. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

    Time frame: First Dose: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose) and Day 2 pre-dose; Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)

  27. Area Under the Concentration-time Curve Over the Dosing Interval (AUC0-tau)

    Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The AUCs were calculated using linear up/log down method. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

    Time frame: Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)

  28. Number of Participants With Adverse Events (AEs) up to Discharge

    An AE was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical (investigational or non-investigation) product. An AE does not necessarily have a causal relationship with the study intervention. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: * Resulted in death * Was life threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent disability/incapacity * Was a congenital anomaly/birth defect * Was an important medical event

    Time frame: Day -2 to Day 12

  29. Number of Participants With Treatment-emergent Adverse Events

    An AE was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical (investigational or non-investigation) product. An AE does not necessarily have a causal relationship with the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: * Resulted in death * Was life threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent disability/incapacity * Was a congenital anomaly/birth defect * Was an important medical event

    Time frame: Day 1 to Day 28

07

Results

Posted Oct 7, 2025

Participant flow

A total of 142 participants were enrolled and inoculated with challenge virus (Respiratory Syncytial Virus \[RSV\]-A Memphis 37b) of which 141 participants were randomized 1:1:1 into one of three treatment groups to receive EDP-323 (at two different doses) or placebo at one site in the United Kingdom between November 2023 and July 2024.

Participant flow — Overall Study
MilestoneEDP-323 High DoseEDP-323 Low DosePlaceboEnrolled But Not Randomized
Started4747471
Completed4747460
Not completed0011
Withdrew: Lost to follow-up0011

Outcome measures

PrimaryQuantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC)

Measured by qRT-PCR in nasal samples.

Time frame:
Day 1 to Day 12
Reported as:
Mean · log10 copies/mL*hours
Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC)
log10 copies/mL*hoursEDP-323 High DoseEDP-323 Low DosePlacebo
Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC)99.05 ± 133.32582.28 ± 158.033657.45 ± 396.743
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in least square (ls) means: -540.56 · 95% CI -680.80 to -400.33
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -523.12 · 95% CI -674.46 to -371.78
  • EDP-323 High Dose vs EDP-323 Low Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls means: -536.30 · 95% CI -641.71 to -430.89
SecondaryqRT-PCR: RSV Peak Viral Load (VLPEAK)

Measured by qRT-PCR in nasal samples.

Time frame:
Day 1 to Day 12
Reported as:
Mean · log10 copies/mL
qRT-PCR: RSV Peak Viral Load (VLPEAK)
log10 copies/mLEDP-323 High DoseEDP-323 Low DosePlacebo
qRT-PCR: RSV Peak Viral Load (VLPEAK)2.52 ± 2.1731.99 ± 2.7116.48 ± 2.311
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -3.83 · 95% CI -4.85 to -2.81
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -4.16 · 95% CI -5.44 to -2.89
SecondaryqRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK

Measured by qRT-PCR in nasal samples.

Time frame:
Day 1 to Day 12
Reported as:
Mean · days
qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK
daysEDP-323 High DoseEDP-323 Low DosePlacebo
qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK2.89 ± 2.9223.12 ± 3.1133.12 ± 1.555
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = 0.6330 · Difference in ls mean: -0.29 · 95% CI -1.50 to 0.92
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = 0.8309 · Difference in ls mean: -0.14 · 95% CI -1.46 to 1.17
SecondaryqRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity

The time from the assessment at the time of the first dose of IMP to qRT-viral load negativity was analyzed using the Kaplan-Meier method. Viral load negativity was reached at the first time when the viral load was undetectable (\< lower limit of detection \[LLOD\]) by qRT-PCR, after which no further detectable assessment appeared. Measured by qRT-PCR in nasal samples.

Time frame:
Day 1 to Day 12
Reported as:
Median · days
qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity
daysEDP-323 High DoseEDP-323 Low DosePlacebo
qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity2.3 (1.0 to 6.5)1.5 (0.5 to 6.0)8.5 (6.5 to NA)
SecondaryqRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load

Time to first negative slope = time of the timepoint after which there are two consecutive declines in viral load - time of the nearest viral load assessment to the first dose of IMP. Measured by qRT-PCR in nasal samples.

Time frame:
Day 1 to Day 12
Reported as:
Mean · days
qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load
daysEDP-323 High DoseEDP-323 Low DosePlacebo
qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load0.77 ± 0.9541.33 ± 2.3602.60 ± 1.632
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = 0.0021 · Difference in ls mean: -1.57 · 95% CI -2.53 to -0.61
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = 0.0905 · Difference in ls mean: -1.09 · 95% CI -2.35 to 0.18
SecondaryqRT-PCR: RSV Viral Load Clearance Rate - EDP-323 High Dose

Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. The model was a distinct analysis for the EDP-323 high dose and placebo groups where the estimates for both groups are model-dependent and impacted by the overall model. A negative slope indicated that the viral load decreased over time. Measured by qRT-PCR in nasal samples.

Time frame:
Up to Day 16
Reported as:
Number · log10 copies/mL/day
qRT-PCR: RSV Viral Load Clearance Rate - EDP-323 High Dose
log10 copies/mL/dayEDP-323 High DosePlacebo
qRT-PCR: RSV Viral Load Clearance Rate - EDP-323 High Dose-0.5650 (-0.7539 to -0.3761)-1.3299 (-1.4775 to -1.1823)
SecondaryqRT-PCR: RSV Viral Load Clearance Rate - EDP-323 Low Dose

Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. The model was a distinct analysis for the EDP-323 low dose and placebo groups where the estimates for both groups are model-dependent and impacted by the overall model. A negative slope indicated that the viral load decreased over time. Measured by qRT-PCR in nasal samples.

Time frame:
Up to Day 16
Reported as:
Number · log10 copies/mL/day
qRT-PCR: RSV Viral Load Clearance Rate - EDP-323 Low Dose
log10 copies/mL/dayEDP-323 Low DosePlacebo
qRT-PCR: RSV Viral Load Clearance Rate - EDP-323 Low Dose-0.5480 (-0.8182 to -0.2778)-1.3298 (-1.4896 to -1.1699)
SecondaryViral Culture: RSV VL-AUC

Measured by viral culture (plaque assay) in nasal samples.

Time frame:
Day 1 to Day 12
Reported as:
Mean · log10 plaque-forming units (PFU)/mL*h
Viral Culture: RSV VL-AUC
log10 plaque-forming units (PFU)/mL*hEDP-323 High DoseEDP-323 Low DosePlacebo
Viral Culture: RSV VL-AUC3.82 ± 9.3336.21 ± 15.448227.04 ± 189.998
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -203.63 · 95% CI -272.18 to -135.07
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -215.03 · 95% CI -288.84 to -141.22
SecondaryViral Culture: RSV VLPEAK

Measured by viral culture (plaque assay) in nasal samples.

Time frame:
Day 1 to Day 12
Reported as:
Mean · log10 PFU/mL
Viral Culture: RSV VLPEAK
log10 PFU/mLEDP-323 High DoseEDP-323 Low DosePlacebo
Viral Culture: RSV VLPEAK0.04 ± 0.1980.16 ± 0.5693.45 ± 2.191
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -3.22 · 95% CI -4.05 to -2.40
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -3.23 · 95% CI -4.11 to -2.34
SecondaryViral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK

Measured by viral culture (plaque assay) in nasal samples.

Time frame:
Day 1 to Day 12
Reported as:
Mean · days
Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK
daysEDP-323 High DoseEDP-323 Low DosePlacebo
Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK5.82 ± 2.9805.78 ± 3.3043.95 ± 2.290
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = 0.0238 · Difference in ls mean: 1.44 · 95% CI 0.20 to 2.68
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = 0.0134 · Difference in ls mean: 1.68 · 95% CI 0.36 to 2.99
SecondaryViral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity

Measured by viral culture (plaque assay) in nasal samples.

Time frame:
Day 1 to Day 12
Reported as:
Median · days
Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity
daysEDP-323 High DoseEDP-323 Low DosePlacebo
Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity0.5 (0.5 to NA)0.5 (0.5 to NA)4.5 (4.5 to 5.5)
SecondaryViral Culture: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load

Measured by viral culture (plaque assay) in nasal samples.

Time frame:
Day 1 to Day 12
Reported as:
Mean · days
Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load
daysEDP-323 High DoseEDP-323 Low DosePlacebo
Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load0.00 ± 0.0000.00 ± 0.0002.92 ± 1.739
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = 0.0389 · Difference in ls mean: -2.18 · 95% CI -4.23 to -0.12
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = 0.2713 · Difference in ls mean: -1.31 · 95% CI -3.73 to 1.10
SecondaryViral Culture: RSV Viral Load Clearance Rate

Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. A negative slope indicated that the viral load decreased over time. Measured by viral culture in nasal samples.

Time frame:
Up to Day 16
Reported as:
Number · log10 PFU/mL/day
Viral Culture: RSV Viral Load Clearance Rate
log10 PFU/mL/dayEDP-323 High DoseEDP-323 Low DosePlacebo
Viral Culture: RSV Viral Load Clearance Rate-0.1336 (-0.7642 to 0.4970)-0.2565 (-0.6990 to 0.1861)-1.1124 (-1.2522 to -0.9727)
SecondaryArea Under the Total Symptom Score (TSS)-Time Curve (TSS-AUC)

An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome. The calculation of the TSS-AUC was performed on the TSS measured 3 times a day using the trapezoidal summation rule based on actual time intervals in hours.

Time frame:
Day 1 to Day 12
Reported as:
Mean · score*hours
Area Under the Total Symptom Score (TSS)-Time Curve (TSS-AUC)
score*hoursEDP-323 High DoseEDP-323 Low DosePlacebo
Area Under the Total Symptom Score (TSS)-Time Curve (TSS-AUC)127.31 ± 149.22182.67 ± 100.412369.10 ± 330.397
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -280.61 · 95% CI -404.44 to -156.77
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -301.15 · 95% CI -428.53 to -173.76
SecondaryPeak TSS

Defined as the highest recorded value of TSS. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.

Time frame:
Day 1 to Day 12
Reported as:
Mean · score on a scale
Peak TSS
score on a scaleEDP-323 High DoseEDP-323 Low DosePlacebo
Peak TSS2.65 ± 1.7652.35 ± 2.6735.77 ± 4.439
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -3.64 · 95% CI -5.26 to -2.02
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -3.70 · 95% CI -5.35 to -2.05
SecondaryTime to Peak TSS

Time to peak TSS = time of peak TSS - time of the nearest TSS assessment to the first dose of IMP. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.

Time frame:
Day 1 to Day 12
Reported as:
Mean · days
Time to Peak TSS
daysEDP-323 High DoseEDP-323 Low DosePlacebo
Time to Peak TSS2.00 ± 2.4032.84 ± 3.1253.36 ± 2.065
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = 0.0552 · Difference in ls mean: -1.08 · 95% CI -2.19 to 0.03
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = 0.5599 · Difference in ls mean: -0.38 · 95% CI -1.69 to 0.92
SecondaryTime to Resolution From Peak TSS

Time to resolution from peak TSS = time of the first 24-hour symptom-free time point - time of peak TSS. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.

Time frame:
Day 1 to Day 12
Reported as:
Mean · days
Time to Resolution From Peak TSS
daysEDP-323 High DoseEDP-323 Low DosePlacebo
Time to Resolution From Peak TSS2.16 ± 1.9222.58 ± 2.4152.93 ± 1.789
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = 0.0307 · Difference in ls mean: -1.04 · 95% CI -1.97 to -0.10
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = 0.4119 · Difference in ls mean: -0.53 · 95% CI -1.81 to 0.76
SecondaryTotal Weight of Nasal Discharge (Mucus) Produced

Each participant was given pre-weighed packets of paper tissues. Participants were asked to place single tissues used for nose blowing or sneezing into a specified collection bag (for that participant only).

Time frame:
Day 1 to Day 12
Reported as:
Mean · grams
Total Weight of Nasal Discharge (Mucus) Produced
gramsEDP-323 High DoseEDP-323 Low DosePlacebo
Total Weight of Nasal Discharge (Mucus) Produced6.12 ± 6.5649.49 ± 20.53716.44 ± 22.152
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = 0.0042 · Difference in ls mean: -13.37 · 95% CI -22.34 to -4.40
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = 0.0058 · Difference in ls mean: -13.19 · 95% CI -22.38 to -4.00
SecondaryTotal Number of Tissues Used

Each participant was given pre-weighed packets of paper tissues. Participants were asked to place single tissues used for nose blowing or sneezing into a specified collection bag (for that participant only).

Time frame:
Day 1 to Day 12
Reported as:
Mean · tissues
Total Number of Tissues Used
tissuesEDP-323 High DoseEDP-323 Low DosePlacebo
Total Number of Tissues Used17.62 ± 23.32916.22 ± 21.45728.79 ± 27.580
Statistical analysis
  • EDP-323 High Dose vs Placebo · ANCOVA · p = 0.0026 · Difference in ls mean: -18.72 · 95% CI -30.61 to -6.84
  • EDP-323 Low Dose vs Placebo · ANCOVA · p = 0.0022 · Difference in ls mean: -19.28 · 95% CI -31.30 to -7.26
SecondaryMaximum Plasma Concentration (Cmax)

Plasma pharmacokinetic (PK) parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, below the limit of quantification (BQL) values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

Time frame:
First Dose: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose) and Day 2 pre-dose; Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax)
ng/mLEDP-323 High DoseEDP-323 Low Dose
First Dose: EDP-3231358.47 ± 590.1911453.70 ± 627.552
Last Dose: EDP-3231703.09 ± 746.730759.38 ± 322.938
First Dose: EP-0387251225.02 ± 753.8821501.55 ± 776.020
Last Dose: EP-0387251294.19 ± 772.921381.94 ± 266.839
First Dose: EP-0390825.40 ± 5.2656.59 ± 4.923
Last Dose: EP-0390826.41 ± 5.1311.40 ± 1.346
SecondaryTime to Cmax (Tmax)

Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

Time frame:
First Dose: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose) and Day 2 pre-dose; Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Reported as:
Median · hours
Time to Cmax (Tmax)
hoursEDP-323 High DoseEDP-323 Low Dose
First Dose: EDP-3233.98 (1.0 to 10.2)3.92 (1.9 to 9.9)
Last Dose: EDP-3234.82 (2.0 to 9.9)4.10 (1.0 to 10.3)
First Dose: EP-0387253.97 (1.9 to 10.2)3.85 (1.9 to 9.9)
Last Dose: EP-0387254.92 (2.0 to 9.9)3.98 (1.0 to 10.0)
First Dose: EP-0390823.00 (0.0 to 9.9)2.97 (0.9 to 9.9)
Last Dose: EP-0390823.82 (1.0 to 9.9)2.00 (0.0 to 7.9)
SecondaryTerminal Half-life (t1/2)

Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Reported as:
Mean · hours
Terminal Half-life (t1/2)
hoursEDP-323 High DoseEDP-323 Low Dose
EDP-32313.07 ± 4.79312.55 ± 4.621
EP-03872516.56 ± 3.04917.16 ± 3.103
EP-0390823.89 ± 1.346—
SecondaryApparent Systemic Clearance at Steady-state (CLss/F)

Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Reported as:
Mean · L/h
Apparent Systemic Clearance at Steady-state (CLss/F)
L/hEDP-323 High DoseEDP-323 Low Dose
EDP-32332.39 ± 13.64824.51 ± 11.383
SecondaryTerminal Elimination Rate Constant (λz)

Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Reported as:
Mean · per hour
Terminal Elimination Rate Constant (λz)
per hourEDP-323 High DoseEDP-323 Low Dose
EDP-3230.06 ± 0.0180.06 ± 0.019
EP-0387250.04 ± 0.0090.04 ± 0.008
EP-0390820.17 ± 0.061—
SecondaryApparent Volume of Distribution at Steady-state (Vss/F)

Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Reported as:
Mean · liters
Apparent Volume of Distribution at Steady-state (Vss/F)
litersEDP-323 High DoseEDP-323 Low Dose
EDP-323569.26 ± 208.202402.73 ± 143.305
SecondaryPlasma Concentration at 12 Hours (C12h) and 24 Hours (C24h)

In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

Time frame:
First Dose: Day 1, 12 and 24 hours post-dose; Last Dose: Day 5, 12 and 24 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentration at 12 Hours (C12h) and 24 Hours (C24h)
ng/mLEDP-323 High DoseEDP-323 Low Dose
First Dose C12h: EDP-323711.96 ± 265.557756.02 ± 345.633
First Dose C24h: EDP-323351.45 ± 166.086368.54 ± 216.140
Last Dose C12h: EDP-323935.04 ± 318.005423.38 ± 203.294
Last Dose C24h: EDP-323493.16 ± 250.229220.69 ± 141.715
First Dose C12h: EP-038725189.71 ± 94.962221.48 ± 162.256
First Dose C24h: EP-03872552.47 ± 27.36256.57 ± 23.845
Last Dose C12h: EP-038725281.01 ± 168.56478.22 ± 39.056
Last Dose C24h: EP-03872596.78 ± 59.54630.29 ± 14.620
First Dose C12h: EP-0390821.28 ± 0.4931.44 ± 0.775
First Dose C24h: EP-0390821.00 ± 0.0001.01 ± 0.041
Last Dose C12h: EP-0390821.60 ± 0.7391.00 ± 0.014
Last Dose C24h: EP-0390821.04 ± 0.1661.00 ± 0.000
SecondaryArea Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last)

Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The AUCs were calculated using linear up/log down method. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

Time frame:
First Dose: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose) and Day 2 pre-dose; Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Reported as:
Mean · h*ng/mL
Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last)
h*ng/mLEDP-323 High DoseEDP-323 Low Dose
First Dose: EDP-32315626.46 ± 5982.74616703.77 ± 7268.939
Last Dose: EDP-32331084.37 ± 13945.73213816.76 ± 7801.297
First Dose: EP-0387257181.42 ± 3848.4388319.19 ± 3563.734
Last Dose: EP-03872510814.63 ± 5619.0053174.73 ± 1641.754
First Dose: EP-03908226.11 ± 21.92831.34 ± 28.251
Last Dose: EP-03908235.35 ± 28.1714.77 ± 4.119
SecondaryArea Under the Concentration-time Curve Over the Dosing Interval (AUC0-tau)

Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The AUCs were calculated using linear up/log down method. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.

Time frame:
Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Reported as:
Mean · h*ng/mL
Area Under the Concentration-time Curve Over the Dosing Interval (AUC0-tau)
h*ng/mLEDP-323 High DoseEDP-323 Low Dose
Last Dose: EDP-32321585.30 ± 7915.4799653.80 ± 4245.794
Last Dose: EP-0387258944.82 ± 4528.0122588.19 ± 1379.765
Last Dose: EP-03908248.21 ± 26.6007.31 ± 10.464
SecondaryNumber of Participants With Adverse Events (AEs) up to Discharge

An AE was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical (investigational or non-investigation) product. An AE does not necessarily have a causal relationship with the study intervention. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: * Resulted in death * Was life threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent disability/incapacity * Was a congenital anomaly/birth defect * Was an important medical event

Time frame:
Day -2 to Day 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) up to Discharge
ParticipantsEDP-323 High DoseEDP-323 Low DosePlacebo
Any AE131515
Any SAE000
SecondaryNumber of Participants With Treatment-emergent Adverse Events

An AE was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical (investigational or non-investigation) product. An AE does not necessarily have a causal relationship with the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: * Resulted in death * Was life threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent disability/incapacity * Was a congenital anomaly/birth defect * Was an important medical event

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsEDP-323 High DoseEDP-323 Low DosePlacebo
Any TEAEs111413
Any Treatment-emergent SAEs000

Adverse events

Collected over All-cause mortality: Day -2 to Day 28; all adverse events: Day -2 to Day 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EDP-323 High Dose0/47 (0%)0/47 (0%)13/47 (27.7%)
EDP-323 Low Dose0/47 (0%)0/47 (0%)15/47 (31.9%)
Placebo0/47 (0%)0/47 (0%)15/47 (31.9%)
Enrolled But Not Randomized0/1 (0%)——
Most frequent other events
Showing 10 of 38
Most frequent other events
EventEDP-323 High DoseEDP-323 Low DosePlaceboEnrolled But Not Randomized
Upper respiratory tract infectionInfections and infestations0/473/471/47—
Viral upper respiratory tract infectionInfections and infestations1/472/471/47—
HeadacheNervous system disorders1/471/472/47—
PresyncopeNervous system disorders2/470/471/47—
Aspartate aminotransferase increasedInvestigations0/470/472/47—
Blood creatine phosphokinase increasedInvestigations0/470/472/47—
Breast abscessInfections and infestations1/470/470/47—
EpididymitisInfections and infestations1/470/470/47—
ParaesthesiaNervous system disorders1/470/470/47—
Sensory disturbanceNervous system disorders0/470/471/47—

Baseline characteristics

Safety Analysis Set (Treated Participants): All participants having received challenge virus and investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(years)EDP-323 High DoseEDP-323 Low DosePlaceboTotal
Mean29.09 ± 6.37227.62 ± 5.98027.91 ± 6.22328.21 ± 6.182
Sex: Female, Male
Sex: Female, Male(Participants)EDP-323 High DoseEDP-323 Low DosePlaceboTotal
Female15171951
Male32302890
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EDP-323 High DoseEDP-323 Low DosePlaceboTotal
White393538112
Black or African American37515
Asian2316
Other3238
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EDP-323 High DoseEDP-323 Low DosePlaceboTotal
Hispanic or Latino1214
Not Hispanic or Latino464546137
08

Study locations

1 site
  • hVIVO Services Limited
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jun 2024, 6 months.

Results were first posted in Oct 2025, 1 year 3 months after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 6 months is below that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 14, 2023
StartActual
Nov 20, 2023
Primary completionActual
Jun 17, 2024
CompletionActual
Jul 12, 2024
Results first posted
Oct 7, 2025
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06170242
Collaborators
hVIVO Services Limited
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Nov 20, 2023
Primary completion
Jun 17, 2024
Completion
Jul 12, 2024
Results posted
Oct 7, 2025
Last update
Oct 7, 2025

Study contacts

Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-323

Start the discussion